ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.80
1.57%
다우존스 지수
38,239.66
0.40%
Bitcoin
62,905.79
-0.80%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Redhill Biopharma Ltd (RDHL)

  7. Redhill Biopharma Ltd (RDHL) 뉴스

RDHL Redhill Biopharma Ltd

0.429
0.01276 (3.06%)
27 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Redhill Biopharma Ltd RDHL 나스닥 주식예탁증서 (DR)
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
0.01276 3.06% 0.429 13:00:05
개장가 저가 고가 종가 전일 종가
0.426 0.422101 0.4339 0.428 0.416243
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
24/04/202420:00PRNUSRedHill Announces First Patient Enrolled in U.S...
08/04/202422:23PRNUSRedHill Biopharma Announces Full-Year 2023 Results and..
02/04/202420:00PRNUSRedHill Biopharma Announces $1.25 Million Registered Direct..
11/03/202420:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/03/202420:00PRNUSRedHill Announces New USPTO Patent Covering Talicia® Through..
05/03/202421:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/03/202421:00PRNUSRedHill's Opaganib Selected for Evaluation by BARDA and NIH..
21/02/202406:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/02/202421:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/02/202421:00PRNUSRedHill's Opaganib Protects Against Radiation-Induced Lung..
16/02/202422:54EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
16/02/202414:15EDGAR2Form EFFECT - Notice of Effectiveness
14/02/202406:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/02/202406:10EDGAR2Form SC 13G - Statement of acquisition of beneficial..
02/02/202400:22EDGAR2Form SC 13G - Statement of acquisition of beneficial..
27/01/202402:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/01/202402:46PRNUSRedHill Biopharma Announces Closing of $8 Million Registered..
26/01/202423:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/01/202423:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
25/01/202423:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/01/202423:05PRNUSRedHill Biopharma Announces $8 Million Registered Direct..
25/01/202420:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/01/202420:00PRNUSRedHill Announces New USPTO Patent Grant for Talicia® for H...
20/12/202322:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202322:45PRNUSRedHill and U.S. Army Announce Opaganib and RHB-107..
12/12/202321:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/12/202321:00PRNUSRedHill Biopharma Regains Compliance with Nasdaq Minimum Bid..
06/12/202321:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202321:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202321:00PRNUSRedHill Announces New, Non-Dilutive External Funding of..
02/12/202306:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/11/202321:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/11/202321:00PRNUSRedHill Biopharma Announces FDA Grant of 5-Year U.S. Market..
17/11/202302:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/11/202322:00PRNUSRedHill Biopharma Announces the Transfer of its Listing to..
27/10/202305:52EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
24/10/202305:06EDGAR2Form F-3/A - Registration statement by foreign private..
17/10/202305:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/10/202321:13EDGAR2Form F-3 - Registration statement by foreign private issuers
10/10/202322:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/10/202320:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/10/202320:00PRNUSRedHill and U.S. Army Announce Opaganib's Ebola Virus..
29/09/202321:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/09/202305:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/09/202305:15PRNUSRedHill Biopharma Announces Receipt of Nasdaq Notification..
18/09/202320:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/09/202320:00PRNUSRedHill Announces FDA sNDA Approval for Talicia®
05/09/202320:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/09/202320:00PRNUSRedHill Announces New USPTO Notice of Patent Allowance for..
17/08/202320:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

최근 히스토리

NASDAQ
RDHL
Redhill Biopharma
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유